# Framingham Risk Score Calculator

> The Framingham risk score estimates your 10-year heart disease risk from age, cholesterol, blood pressure, and smoking.

**Last updated:** September 2026
**URL:** https://bodyhealthcalculator.com/framingham-risk-calculator
**Category:** Heart & Cardiovascular

## How it works

Simplified Framingham point-based scoring for 10-year hard CVD event risk.

## What is the Framingham risk score?

The Framingham Heart Study, launched in 1948 in Framingham, Massachusetts, identified major risk factors for cardiovascular disease through decades of prospective follow-up.

Risk scores derived from Framingham data estimate the probability of a heart attack, stroke, or other hard cardiovascular event over the next ten years. They combine age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, smoking status, and blood pressure treatment into a single percentage. The output helps clinicians and patients discuss whether lifestyle changes alone are enough or whether statins and tighter risk-factor control are warranted.

Framingham scores were developed primarily in a white middle-class cohort. They may over- or underestimate risk in other ethnic groups. Some guidelines prefer the Pooled Cohort Equations (ASCVD risk calculator) for diverse US populations.

Sources: [1] [2]

## How this Framingham calculator works

Enter age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure treatment, and smoking status. This page applies a simplified educational point heuristic and multiplies its point total by 2.5, capped from 1% to 40%. It does not implement the published 2008 Framingham regression equation, and its percentage should not be used as a validated ten-year risk estimate.

Published Framingham models differ by outcome. The 2008 general CVD model predicts coronary disease, stroke or transient ischemic attack, peripheral artery disease, and heart failure, and it includes diabetes. Hard coronary models predict narrower outcomes such as myocardial infarction and coronary death. This tool omits diabetes and therefore cannot reproduce either the full general CVD model or current ASCVD equations.

Risk is a population estimate. Two people with identical scores can have different outcomes based on family history, inflammatory markers, lipoprotein(a), and lifestyle trajectories not captured in the score.

*Simplified point logic implemented on this page*

| Input | Men | Women |
| --- | --- | --- |
| Age | Below 50: 2; 50 to 59: 4; 60 or older: 5 | Below 50: 0; 50 to 59: 4; 60 or older: 6 |
| Total cholesterol | 200 to 239: 2; 240 or higher: 3 | 240 or higher: 2 |
| Low HDL | Below 40: 2 | Below 50: 2 |
| Systolic pressure | 130 to 139: 1; 140 or higher: 2 treated, 3 untreated | 140 or higher: 2 treated, 3 untreated |
| Current smoking | 4 | 3 |
| Displayed estimate | Points x 2.5%, capped at 1% to 40% | Points x 2.5%, capped at 1% to 40% |

Sources: [1] [3]

## Understanding your risk category

Ten-year risk below 10% is generally considered low. Ten to twenty percent is intermediate. At or above 20% is high risk.

The 2019 ACC/AHA primary prevention guideline advises shared decision-making about statins when ten-year ASCVD risk is 7.5% or higher in adults 40 to 75, with intensity matched to risk category. Young adults may show low ten-year risk despite dangerous lifetime exposure if they smoke or have very high LDL. Lifetime risk tools and coronary artery calcium scoring supplement short-term Framingham estimates in selected patients.

People with diabetes, LDL above 190 mg/dL, or established cardiovascular disease are often treated as high risk regardless of Framingham score and qualify for intensive treatment without further calculation.

*Framingham 10-year hard CVD risk categories. ATP III and ACC/AHA risk stratification.*

| 10-year risk | Category | Typical management |
| --- | --- | --- |
| Below 5% | Low | Lifestyle modification |
| 5 to 7.4% | Borderline | Consider risk enhancers; lifestyle |
| 7.5 to 19.9% | Intermediate | Statin may be considered |
| 20% and above | High | Statin recommended; intensive risk factor control |

Sources: [2] [4]

## How to lower cardiovascular risk

Smoking cessation produces the fastest relative risk reduction of any modifiable factor.

Systolic blood pressure control to below 130 mmHg, LDL reduction (often with statins), regular aerobic activity, and a diet emphasizing vegetables, whole grains, and unsaturated fats each independently lower event rates. Aspirin for primary prevention is no longer routinely recommended for low-to-moderate risk adults because bleeding risk often outweighs benefit. Your clinician weighs age, bleeding history, and overall risk.

Reassess risk every four to six years in adults 40 to 75, or sooner when risk factors change substantially.

Sources: [3] [4] [5]

## How the published Framingham equation differs

D'Agostino and colleagues derived sex-specific Cox models in 8,491 Framingham participants aged 30 to 74 who were free of CVD. During 12 years, 1,174 had a first event. Predictors were age, total cholesterol, HDL cholesterol, systolic pressure, antihypertensive treatment, smoking, and diabetes. The model showed C statistics of 0.763 in men and 0.793 in women in the development data.

The published calculation uses natural-log transformed continuous values, sex-specific regression coefficients, a mean risk-factor sum, and baseline survival. In compact form, risk equals 1 minus baseline survival raised to exp(sum of coefficient times log predictor minus the sex-specific mean). That structure preserves more information than coarse point bands. The on-page shortcut does not use those coefficients or baseline survival.

Sources: [1] [6]

## How to use this page safely

Use recent resting systolic pressure and a laboratory total cholesterol and HDL result in mg/dL. Mark smoking yes only for current smoking, and mark treatment yes if prescribed blood pressure medicine is being taken. Enter sex as required by the displayed heuristic. Calculate once with accurate inputs, save the inputs and result, and treat the output as a prompt to obtain a validated clinical estimate.

For a treatment decision, ask a clinician to use a current guideline-supported calculator whose variables and outcome match the decision. The ACC tool now presents PREVENT alongside the older Pooled Cohort Equations. PREVENT estimates total CVD, ASCVD, and heart failure in adults without known CVD and incorporates kidney function. A number from one model cannot be inserted into thresholds written for another outcome.

Sources: [2] [7] [8]

## Worked cases using this page

Case 1: a 55-year-old man with total cholesterol 220, HDL 50, systolic pressure 132 without treatment, and no smoking receives 4 age points, 2 cholesterol points, 1 pressure point, and no other points. Seven points produces a displayed 17.5%, labeled intermediate. That number is the site heuristic, not the result of the 2008 Framingham equation.

Case 2: a 55-year-old woman with the same inputs receives 4 age points and no additional points, producing 10%. The large sex difference illustrates how coarse rules can jump at cutoffs. If her HDL were 49, two points would be added immediately. A validated equation handles continuous predictors differently and also considers diabetes. Do not infer an exact treatment benefit from either worked output.

Sources: [1] [6]

## Risk categories and treatment conversations

Current ACC/AHA categories for validated ten-year ASCVD estimates are low below 5%, borderline from 5% to below 7.5%, intermediate from 7.5% to below 20%, and high at 20% or above. These categories were built around Pooled Cohort Equation prevention decisions, not this simplified score. Risk enhancers and coronary artery calcium can refine a borderline or intermediate decision.

The USPSTF recommends a statin for selected adults aged 40 to 75 with at least one CVD risk factor and validated ten-year risk of 10% or more, and selective offering from 7.5% to below 10%. Adults with established ASCVD, LDL cholesterol at least 190 mg/dL, or some diabetes profiles follow separate pathways and should not wait for a shortcut score.

*ACC/AHA categories for a validated ten-year ASCVD estimate*

| Validated estimate | Category | Usual discussion |
| --- | --- | --- |
| Below 5% | Low | Lifestyle and risk-factor follow-up |
| 5% to below 7.5% | Borderline | Review risk enhancers |
| 7.5% to below 20% | Intermediate | Discuss statin and possible CAC |
| 20% or higher | High | Intensive prevention discussion |

Sources: [2] [3] [9]

## Screening, medications, and urgent symptoms

Risk estimation screens for future event probability; it does not diagnose blocked arteries or explain current symptoms. A low result cannot exclude coronary disease. Chest pressure, severe breathlessness, fainting, or new weakness, facial droop, or speech difficulty requires urgent assessment regardless of score. People with prior myocardial infarction, stroke, symptomatic PAD, or revascularization already have clinical ASCVD and need secondary prevention care.

Do not start aspirin from this output. The USPSTF recommends an individual decision only for selected adults aged 40 to 59 with at least 10% validated ten-year CVD risk and low bleeding risk, and recommends against initiating primary-prevention aspirin at age 60 or older. Statins also require a benefit, harm, interaction, pregnancy, and preference discussion. Never stop prescribed therapy because a recalculated score falls.

Sources: [2] [9] [10]

## Limitations

Simplified point scores approximate published Framingham variants. They do not replicate them. Clinical decisions should use validated tools aligned with current national guidelines.

The score does not apply to people with prior heart attack, stroke, or known atherosclerotic disease. They are already in the highest treatment tier clinically.

Calibration matters as much as ranking. An external study in middle-aged European men found that the uncalibrated 2008 equation overestimated combined coronary and stroke events by about 1.9-fold, while recalibration improved fit. Baseline event rates, preventive treatment, and population characteristics change absolute estimates. Framingham development participants were predominantly White residents of one Massachusetts community, limiting direct transport to every population.

The page has additional implementation limits. Its age rules do not enforce the published 30 to 74 year range, cholesterol and pressure are grouped coarsely, diabetes is absent, and some point assignments differ sharply by sex. It also labels 10% to below 20% intermediate, while current ASCVD prevention categories use other boundaries. These limitations are large enough that the displayed percentage should be treated as educational output rather than an approximate clinical Framingham score. Clinical recalculation is necessary.

Sources: [1]

## FAQ

### What Framingham risk is high?

≥20% 10-year risk is high. 10 to 20% is intermediate. Statins are often considered for high risk.

## References

1. D'Agostino et al.. [General cardiovascular risk profile for use in primary care](https://pubmed.ncbi.nlm.nih.gov/18212285/)
2. Arnett et al.. [2019 ACC/AHA Guideline on Primary Prevention of CVD](https://pubmed.ncbi.nlm.nih.gov/30879355/)
3. Grundy et al.. [2018 AHA/ACC Cholesterol Clinical Practice Guideline](https://pubmed.ncbi.nlm.nih.gov/30586774/)
4. Framingham Heart Study. [Framingham Heart Study](https://www.framinghamheartstudy.org/)
5. CDC. [Smoking cessation and cardiovascular risk reduction](https://www.cdc.gov/tobacco/quit_smoking/how_to_quit/benefits/index.htm)
6. Framingham Heart Study. [Cardiovascular Disease 10-Year Risk Function](https://www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/)
7. Khan et al.. [Development and Validation of the PREVENT Equations](https://pubmed.ncbi.nlm.nih.gov/37947085/)
8. American College of Cardiology. [CVD Risk Estimator Plus](https://tools.acc.org/CVD-Risk-Estimator-Plus/)
9. USPSTF. [Statin Use for Primary Prevention](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication)
10. USPSTF. [Aspirin Use to Prevent Cardiovascular Disease](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-use-to-prevent-cardiovascular-disease-preventive-medication)

## Related

- [cvd risk calculator](https://bodyhealthcalculator.com/cvd-risk-calculator.md)
- [cholesterol ratio calculator](https://bodyhealthcalculator.com/cholesterol-ratio-calculator.md)
- [ldl calculator](https://bodyhealthcalculator.com/ldl-calculator.md)